Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic

Ken-ichiro Tanaka1, Toru Yamaguchi, Hiroshi Kaji

  • 1Department of Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Japan. ken1nai@med.shimane-u.ac.jp

Insights

Advanced glycation end products (AGEs) impair bone formation by disrupting endoplasmic reticulum (ER) stress pathways in osteoblasts. This study reveals how AGEs inhibit osteoblast differentiation, contributing to bone quality decline in diabetes mellitus.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Bone Biology

Background:

  • Advanced glycation end products (AGEs) contribute to bone quality deterioration in diabetes mellitus.
  • Previous studies show AGE2/AGE3 inhibit osteoblast differentiation and induce apoptosis in ST2 cells.
  • The role of endoplasmic reticulum (ER) stress in AGE-induced effects on osteoblasts is unknown.

Purpose of the Study:

  • To investigate the role of ER stress in AGE2- or AGE3-induced suppression of osteoblastogenesis in mouse stromal ST2 cells.

Main Methods:

  • ST2 cells were treated with AGE2 or AGE3, and ER stress was induced with thapsigargin (TG).
  • Osteoblastic differentiation markers (Osterix, Col1, ALP, OCN mRNA) and ER stress sensors (IRE1α, ATF6, OASIS, PERK, ATF4) were analyzed.
  • PERK levels were reduced using siRNA to assess its role.

Main Results:

  • Thapsigargin induced osteoblastic differentiation in ST2 cells.
  • AGE2 and AGE3 suppressed ER stress sensors (IRE1α, ATF6, OASIS) but increased PERK and ATF4.
  • Reducing PERK levels did not alter AGE-induced suppression of osteoblast differentiation markers.

Conclusions:

  • AGEs inhibit osteoblastic differentiation by suppressing ER stress sensors and accumulating abnormal proteins.
  • This mechanism likely contributes to AGE-induced bone formation suppression in diabetes mellitus.